- Home
- NVO
NVO
Novo Nordisk A/S
as 03-28-2025 4:00pm EST
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
| Founded: | 1923 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 530.0B | IPO Year: | N/A |
| Target Price: | $141.67 | AVG Volume (30 days): | 7.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
| EPS: | 3.14 | EPS Growth: | 21.54 |
| 52 Week Low/High: | $69.18 - $148.15 | Next Earning Date: | 05-07-2025 |
| Revenue: | $40,314,376,667 | Revenue Growth: | 25.03% |
| Revenue Growth (this year): | 22.57% | Revenue Growth (next year): | 17.01% |
Latest Novo Nordisk A/S News
NVO Breaking Stock News: Dive into NVO Ticker-Specific Updates for Smart Investing
Investing.com
15 hours ago
BofA cuts Novo Nordisk shares target on expected Q1 earnings miss
Zacks
16 hours ago
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Reuters
17 hours ago
BoFA says Novo Nordisk may miss Q1 expectations as Wegovy, Ozempic sales lag
MT Newswires
17 hours ago
Lexicon Pharmaceuticals Enters License Agreement With Novo Nordisk for Obesity Drug; Shares Jump
Moneywise
19 hours ago
Novo Nordisk’s $2B deal for obesity drug a strategic game-changer for US pharmaceutical market
Quartz
20 hours ago
Cheaper Wegovy, 23andMe shutters, and RFK Jr. cuts FDA jobs: Pharma news roundup
Motley Fool
a day ago
Why Novo Nordisk Stock Dipped on Thursday
Quartz
a day ago
Wegovy sales took a hit this year. Novo's CEO blames off-brand competition
Compare NVO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVO Novo Nordisk A/S - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.